← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #151 OF 1,000 MOST-CITED

Management review - defined interval, sufficient frequency

FDA cited this observation 154 times across 144 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Devices154
BY FISCAL YEAR
FY20267
FY202518
FY202422
FY202325
FY202217
FY20214
FY20209
FY201916
FY201821
FY201715

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 1.7× the rate of the average FDA-cited firm (14.6% vs 8.3%), across 144 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your Professional access…

How FDA worded it — real examples

Management with executive responsibility has not reviewed the suitability and effectiveness of the quality system at defined intervals.

Pleural Dynamics, Inc. · Minnetonka, Minnesota · Devices · 2026-01-13

Management with executive responsibility has not reviewed the suitability and effectiveness of the quality system at defined intervals.

3B Medical, Inc. · Dublin, Ohio · Devices · 2025-12-10

Management with executive responsibility has not reviewed the suitability and effectiveness of the quality system at defined intervals.

Unetixs Vascular, Inc. · Warwick, Rhode Island · Devices · 2025-12-04

Management with executive responsibility has not reviewed the suitability and effectiveness of the quality system at defined intervals.

Banyan USA LLC · Hauppauge, New York · Devices · 2025-11-12

Management with executive responsibility has not reviewed the suitability and effectiveness of the quality system at defined intervals and with sufficient frequency.

Tarmac Products, Inc. · Miami Gardens, Florida · Devices · 2025-11-04

Management with executive responsibility has not reviewed the suitability and effectiveness of the quality system.

Retmap Inc · Chicago, Illinois · Devices · 2025-10-30

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Medical devices

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →